The CEO of French neurotechnology startup Robeauté says its microrobot could unlock precise delivery of drugs and other therapies directly into the brain,
The microrobots, which are each the size of grain of rice, are able to reach areas that are difficult to access with existing treatments.
Joana Cartocci says the company is targeting first-in-human studies in 2027 and a market launch in the early 2030s.
She spoke to Tom Mackenzie on the latest episode of Bloomberg Tech: Europe.
——–
Like this video? Subscribe to Bloomberg Technology on YouTube:
Watch the latest full episodes of “Bloomberg Technology” with Caroline Hyde and Ed Ludlow here:
Get the latest in tech from Silicon Valley and around the world here:
Connect with us on…
X:
Facebook:
Instagram:
Follow Ed Ludlow on X here:
Follow Caroline Hyde on X here:
Listen to the daily Bloomberg Technology podcast here:
More from Bloomberg Business
Connect with us on…
X:
Facebook:
Instagram:
LinkedIn:
TikTok:
source
